Futur Publishes Annual and Sustainability Report for 2024
Today, Futur Pension AB (publ) publishes its Annual and Sustainability Report for 2024. Read it at www.futur.se/financial-information
We are pleased to note that Futur's customers overall have experienced strong returns in 2024. In particular, customers with exposure to global equities, led by the U.S. market, have seen significant growth of their capital. Thereto, we are proud of high inflows of new savings and pension capital.
In line with last years, Futur has continued to invest heavily in its technology platform to ensure a high level of service and cost efficiency.
'For the coming years, we see great opportunities to continue growing by developing innovative and efficient services for savings and pension together with our partners. In 2025, we will continue our investments in digital self-service solutions to strengthen our position as the obvious choice for savings and pensions. We also look forward to more and deeper collaborations throughout the year,' says Torgny Johansson, CEO of Futur.
Key highlights 2024:
New digital self-service interface for private customers which has contributed to reducing routine calls to customer service by more than 30%
Awarded most innovative company and the company with the best product range in Origo's annual survey among financial advisors in Sweden
4 new partners and 23,000 new customers
80% Y-on-Y growth in the occupational pension portfolio bond product
Continued revenue growth (+24% Y-on-Y) and 50% higher net inflows than in 2023
Futur's positive development continued in 2024, and the profit grew by 33% to 420 million SEK (compared to SEK 316m in 2023). This increase is explained by growing net inflows, strong returns on customers' capital, and cost efficiency.
Key financial figures 2024 (2023):
Futur provides digital infrastructure for the savings and pension market. With our modern platform, we efficiently connect products and customers through partners who offer professional advice. Our platform enables partners to offer better savings options cost-effectively, helping more people achieve a richer and more secure future. Futur has more than 50 partners and 300,000 customers, with 235 billion SEK in savings and pension capital. For more information, visit www.futur.se
The information was submitted for publication, through the agency of the contact persons set out above, at 2025-03-17 11:00 CET.
Torgny Johansson, CEO, 08-502 225 00
[email protected]
Copyright Business Wire 2025.
PUB: 03/17/2025 09:03 AM/DISC: 03/17/2025 09:03 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Biovica Resolves on a Fully Guaranteed Rights Issue of Approximately SEK 80 million at SEK 0.63 Per Share
NOT TO BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OF AMERICA, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. REFER TO THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE. UPPSALA, SE / / June 11, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - INSIDER INFORMATION: The Board of Directors of Biovica International AB (publ) ("Biovica" or the "Company") has today, subject to subsequent approval by an extraordinary general meeting, resolved to carry out a new issue of A-shares and B-shares of approximately SEK 80.1 million with preferential rights for the Company's shareholders (the "Rights Issue") and a directed issue of warrants of series TO 4 B to investors who have entered into guarantee undertakings as top-down guarantors (the "Anchor Investors") (the "Directed Issue of Warrants"). In addition, the Board of Directors has proposed that an extraordinary general meeting resolves to authorise the Board of Directors to resolve on a directed issue of up to 83 291 780 B-shares to the Anchor Investors, provided that the Anchor Investors have not received full allotment in the Rights Issue (the "Oversubscription Option"). The Rights Issue is covered to approximately SEK 80.1 million, corresponding to 100 percent through a combination of subscription and top-down and bottom-up guarantee undertakings. As compensation for the top-down guarantee undertakings in the Rights Issue, free warrants will be issued and allotted in the Directed Issue of Warrants. As compensation for the bottom-up guarantee undertakings, the guarantors will receive a cash compensation of eight percent of the respective guarantors' guaranteed amount. Notice of the extraordinary general meeting will be published through a separate press release. The rationale of the Rights Issue is to (i) continue the Company's focused launch in the US, (ii) conduct service development within pharma, (iii) conduct commercialization in Europe through partnerships where agreements are already signed, and (iv) develop product and production capacity to meet expected volumes, customer needs, and regulatory requirements. The net proceeds from the Rights Issue are expected to cover the Company's working capital needs through Q3 of fiscal year 2026/27, by which time Biovica expects to become cash-flow positive. Summary The Board of Directors of Biovica has today, subject to an approval by an extraordinary general meeting, resolved to carry out a new issue of A-shares and B-shares of approximately SEK 80.1 million with preferential rights for the Company's shareholders and a directed issue of warrants of series TO 4 B to Anchor Investors with deviation from the shareholders' preferential rights. In addition, Biovica's Board of Directors has today proposed that an extraordinary general meeting resolves to authorise the Board of Directors to decide on a directed issue of a maximum of 83 291 780 B-shares to the Anchor Investors, provided that they have not received full allotment in the Rights Issue. The extraordinary general meeting is intended to be held on 14 July 2025. Notice for the extraordinary general meeting will be published through a separate press release. The rationale of the Rights Issue is to (i) continue the Company's focused launch in the US, (ii) conduct service development within pharma, (iii) conduct commercialization in Europe through partnerships where agreements are already signed, and (iv) develop product and production capacity to meet expected volumes, customer needs, and regulatory requirements. The purpose of the Directed Issue of Warrants is to issue warrants free of charge as compensation for top-down anchor guarantee undertakings in the Rights Issue. The subscription price in the Rights Issue is SEK 0.63 per share. The subscription period in the Rights Issue is expected to run during the period 18 July - 1 August 2025. The record date for the right to participate in the Rights Issue is 16 July 2025. The Company has received subscription undertakings of 16.7 million, top-down guarantee undertakings of SEK 52.5 million and bottom-up guarantee undertakings of SEK 10.9 million. The rights issue is hence guaranteed to SEK 80.1 million, corresponding to 100 percent of the Rights Issue. The Company's CEO Anders Rylander has committed to subscribe for his full pro rata share in the transaction, corresponding to SEK 8 million. In addition, he will participate as a top guarantor, committing a further SEK 2 million. A Dutch family office, HDF Impact BV, has committed to act as one of the largest guarantor in the guarantee consortium in the Rights Issue. As a result of its significant guarantee commitment, the family office is expected to become a major shareholder following the completion of the Rights Issue. The Company has entered into a bridge loan agreement with the largest guarantor in the guarantee consortium, the Dutch family office HDF Impact BV, of up to SEK 10 million where repayment of the loan and accrued interest shall be made by set-off of the loan against payment for the subscription in accordance with the lender's guarantee commitment. Biovica's CEO Anders Rylander comments: "During 2024, Biovica has laid the foundation for scaling up sales by reaching several key milestones. In the US, we have achieved clinical validation in collaboration with world-leading oncologists and institutions, obtained FDA approval, established a CMS/Medicare pricing, initiated commercial sales to more than 30 US hospitals, and formed strategic partnerships that enable us to scale further. Together with this fully underwritten share issue, we now have the opportunity to realize our vision - to improve treatment outcomes for patients, optimize care for providers, and create long-term shareholder value." Company overview, background and rationale Introduction Biovica is a biotechnology company that develops and commercializes blood-based diagnostic tests using biomarkers that improve the monitoring and evaluation of modern cancer treatments. The company's first product, DiviTum® TKa, has successfully demonstrated its ability to evaluate therapy effectiveness in several clinical trials and in July 2022 received FDA 510(k) clearance for monitoring treatment in patients with metastatic breast cancer. In 2024, clinical results were presented showing that DiviTum TKa also creates value when monitoring patients with early-stage breast cancer undergoing adjuvant therapy - significantly expanding its potential to benefit many more patients. Established partnerships enable sales growth with existing organization In recent months, Biovica has signed several key agreements that enable sales growth without expanding the current organization. In the US, two main agreements underpin this potential: * An agreement with a major US health insurance and care provider, with revenues exceeding 100 BUSD, serving over 10 million Americans through its insurance policies.* An agreement with Tempus AI, a health technology and precision medicine company that uses artificial intelligence and machine learning to improve cancer care. The US healthcare provider sees great potential in using DiviTum TKa, offering patients more personalized treatment while avoiding unnecessary costs. Usage has already begun and is expected to increase through a large-scale rollout involving a study of approximately 900 patients. This will generate both revenue for Biovica and valuable data for future expansion and potential inclusion in treatment guidelines. In addition to this initial customer, there are several others in the same segment - so-called Integrated Delivery Networks (IDNs) - that could benefit similarly from DiviTum TKa. These potential clients will be a priority for Biovica's own sales team. The agreement with Tempus AI enables a more than hundredfold increase in Biovica's sales force, as Tempus AI's sales representatives will also market DiviTum TKa. They will focus primarily on the community oncologist segment, which includes the largest patient volume. This is a segment that Tempus AI can reach more effectively than Biovica's current team. Tempus AI has a strong incentive, given both the direct margin they earn on DiviTum TKa and the expected boost to their existing product sales. Biovica's current staffing and cost levels are expected to remain unchanged over the next 12 months. Goals and Milestones The Company refers to the press release with new financial targets and expected revenue distribution that was published by the Company on 10 June 2025. Commercial launch and Market potentialSince receiving FDA clearance in July 2022, Biovica has reached several commercial milestones, including certification of its CLIA laboratory in San Diego. Use of ProceedsThe expected net proceeds from the Rights Issue and TO3 B warrants will primarily be used for the following in order of priority as set out below: (i) Continued focused launch in the US (~40%), including: Funding the current sales and marketing organization (e.g., Sales, Market Access, Revenue Cycle). Laboratory personnel to perform analyses at the CLIA lab. Sales support for partners like Tempus AI. (ii) Service development within pharma (~25%), to: Further development of revenue-generating services (e.g., consulting and analysis for pharma partners) Establishing co-development projects to position DiviTum® TKa as a Companion Diagnostic (CDx) with pharma partners (iii) Commercialization in Europe through partnerships where agreements are already signed (~5%). (iv) Product and production capacity development to meet expected volumes, customer needs, and regulatory requirements (~30%). The net proceeds from the Rights Issue - assuming full subscription as per commitments and guarantees - are expected to cover the Company's working capital needs through Q3 of fiscal year 2026/27, by which time Biovica expects to become cash-flow positive. The Rights IssueFor the reasons set out above, the Company's Board of Directors, subject to an approval from an extraordinary general meeting, has decided to carry out the Rights Issue of approximately SEK 80.1 million before transaction costs. Those who are registered as shareholders in Biovica on the record date 16 July 2025 have preferential rights to subscribe for new A-shares and/or B-shares in Biovica in relation to their existing shareholding in the Company. Shareholders receive one (1) subscription right for each share held in the Company. The subscription rights entitle the holder to subscribe for new A-shares and/or B-shares in the Rights Issue, whereby ten (10) subscription rights give the shareholder the right to subscribe for thirteen (13) new A-shares and/or B-shares. In addition, investors are offered the possibility to apply for subscription of shares without subscription rights. The subscription price in the Rights Issue has been set to SEK 0.63 per share. Subscription for new A and/or B-shares shall be made during the period 18 July to 1 August 2025. Trading in subscription rights is expected to take place on Nasdaq First North Premier Growth Market during the period from 18 July to 26 July 2025 and trading in BTA (paid subscribed shares) is expected to occur between 18 July and 20 August 2025. No prospectus will be prepared in connection with the Rights Issue. The Company will prepare and publish a disclosure document in the form prescribed by Regulation (EU) 2024/2809 ("Listing Act") Annex IX. Bridge loan agreementThe Company has entered into a bridge loan agreement with the largest guarantor in the guarantee consortium, the Dutch family office HDF Impact BV, of up to SEK 10 million where repayment of the loan and accrued interest shall be made by set-off of the loan against payment for the subscription in accordance with the lender's guarantee commitment. The bridge loan carries an interest rate of 1.00 percent per 30-day period until the loan is repaid and a commitment fee of 1,00 percent of the loan amount. Subscription and guarantee undertakingsProvided that the extraordinary general meeting approves the Board of Directors' resolution on the Rights Issue, certain existing shareholders have undertaken to subscribe for their respective pro rata share of the Rights Issue, corresponding to a total of approximately 21 percent, or approximately SEK 16.7 million of the Rights Issue. These shareholders have also undertaken to vote in favor of the Rights Issue at the extraordinary general meeting. These shareholders will not receive any compensation for subscribing for their respective pro rata shares of the Rights Issue. The Company's CEO Anders Rylander has committed to subscribe for his full pro rata share in the transaction, corresponding to SEK 8 million. In addition, he will participate as a top guarantor, committing a further SEK 2 million. The Anchor Investors, consisting of several existing shareholders and external investors including the Dutch family office, HDF Impact BV entered into top-down guarantee undertakings for, in total, approximately 66 percent of the Rights Issue, corresponding to approximately SEK 52.5 million. As compensation, the Anchor Investors will receive one (1) warrant of series TO 4 B for each B-share that they undertake to subscribe for in the Rights Issue. In addition, certain external investors have entered into bottom-up guarantee undertakings that comprises of undertakings up to 10,900,000 SEK in the Rights Issue (excluding amounts covered by subscription commitments), which corresponds to approximately 14 percent of the Rights Issue. As compensation, these guarantors receive a cash compensation of eight (8) percent of the respective guarantor's guaranteed amount. The Rights Issue is thus covered by subscription and guarantee undertakings of approximately SEK 80.1 million, corresponding to 100 percent of the Rights Issue. Neither the subscription undertakings nor the guarantee commitments are secured by bank guarantee, blocked funds, pledges or similar arrangements. Further information regarding the parties who have entered into subscription undertakings and guarantee commitments will be provided in the Annex IX disclosure document that will be published prior the commencement of the subscription period. Directed Issue of WarrantsBiovica's Board of Directors has, subject to subsequent approval by an extraordinary general meeting, resolved to carry out a new issue of warrants of series TO 4 B with deviation from the shareholders' preferential rights. The warrants of series TO 4 B shall be issued, free of charge, as compensation for the above-mentioned guarantee undertakings in the Rights Issue. Each warrant of series TO 4 B entitles the holder to one (1) B-share in the Company at an exercise price of SEK 0.95 per B-share up to and including 30 June 2028 and SEK 1.25 per B-share from 1 July 2028 up to and including 30 June 2030. Oversubscription OptionThe Board of Directors of Biovica has proposed that an extraordinary general meeting resolves to authorise the Board of Directors to resolve on a directed issue of a maximum of 83,291,780 B-shares, provided that those who have applied for subscription in the Rights Issue have not received full allotment, which shall be entitled to subscribe for shares under the authorisation. The subscription price for A-shares and B-shares issued under the authorisation as well as the terms and conditions for the Oversubscription Option shall, where applicable, correspond to those applicable to the Rights Issue. Deviation from shareholders' preferential rightsThe Board of Directors has carefully considered the possibility of financing the operations solely through the Rights Issue, but has concluded that the chosen structure is the best alternative for the Company and its shareholders. The Board of Directors considers it advantageous that the guarantors under the guarantee have the right to subscribe for warrants of series TO 4 B free of charge as the warrants constitute an integral and essential part of the compensation for the guarantee commitments which includes a right and obligation for the guarantors to subscribe for shares in the Company corresponding to the guaranteed amount, regardless of whether such subscription takes place under the Rights Issue or, in the event that the guarantors do not receive full allotment under the Rights Issue, through the Oversubscription Option. The Board of Directors considers that the implementation of the Rights Issue without the directed issue of warrants of series TO 4 B and the potential Oversubscription Option, would entail a risk that the Company would lose potential financing opportunities from long-term investors. Furthermore, the Board of Directors, in consultation with its financial advisors, considers that the alternative of carrying out a rights issue with customary terms and conditions and external guarantors would have entailed a higher dilution, a higher discount and a lower secured contribution of net proceeds - with the consequence that the financial targets set by the Company in connection with this Rights Issue could not reasonably have been achieved without additional financing. In light of the above, the Board of Directors considers, after an overall assessment, that the Rights Issue, in combination with the Directed Issue of Warrants and the potential Oversubscription Option, is the most advantageous alternative for the Company to raise capital in a cost and time efficient manner to strengthen the Company's financial position, while maintaining the most value in the Company and being most favorable for the Company's shareholders. The remuneration in the form of issued warrants free of charge has been determined in consultation with financial advisors and after arm's length negotiations with potential underwriters. Against this background, the Board of Directors is of the opinion that the remuneration has been determined on market terms and is deemed to reflect prevailing market conditions. Extraordinary general meetingThe Board of Directors' resolutions regarding the Rights Issue, the Directed Issue of Warrants and the Oversubscription Option are subject to approval by an extraordinary general meeting, which is scheduled to be held on 14 July 2025. A notice for the extraordinary general meeting will be published through a separate press release. Lock-up undertakingsPrior to the execution of the Rights Issue, the Anchor Investors have undertaken not to dispose of any shares subscribed and allocated under the guarantee commitment in the Right Issue and Oversubscription Option up until the date following six months after the subscription period of the Rights Issue ends. Share capital and dilutionProvided that the Rights Issue is fully subscribed, the share capital will increase by approximately SEK 8,474,819.94, from approximately SEK 6,519,092.27 to approximately SEK 14,993,912.21, by issuing 127,122,299 new A-shares and B-shares, resulting in the total number of shares increasing from 97,786,384 to 224,908,683, divided (following rounding in each share class) into 14,423,973 A-shares and 210 484 709 B-shares. Shareholders who choose not to participate in the Rights Issue will have their shareholding diluted by up to 56.52 percent of the capital and approximately 69.70 percent of the votes in the Company (calculated on the total maximum number of outstanding shares in the Company after completion of the Rights Issue). These shareholders have the opportunity to compensate themselves financially for this dilution effect by selling the subscription rights received. Indicative timetable for the Rights IssueThe below timetable for the Rights Issue is preliminary and may be adjusted. 14 July 2025 Extraordinary general meeting 14 July 2025 Last day of trading in the Company's shares, including the right to participate in the Rights Issue 15 July 2025 First day of trading in the Company's shares, excluding the right to participate in the Rights Issue 16 July 2025 Record date for participation in the Rights Issue with preferential rights 17 July 2025 Annex IX disclosure document relating to the Rights Issue is published 18 July - 26 July 2025 Trading in subscription rights 18 July - 1 August 2025 Subscription period 18 July - 20 August 2025 Trading in paid subscribed shares (BTA) 5 August 2025 Estimated announcement of outcome in the Rights Issue AdvisorsZonda Partners AB acts as Sole Global Coordinator and Bookrunner in connection with the Rights Issue. Baker McKenzie acts as legal adviser to Biovica in connection with the Rights Issue. For more information, please contact: Anders Rylander, VDM: +46 76 666 16 47E: Anders Morén, CFOM: +46 73 125 92 46E: This information is inside information that Biovica International AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was submitted for publication, through the agency of the contact persons set out above, at the time specified by the Company's news distributor, MFN, at the time of publication of this press release. About Biovica Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: IMPORTANT INFORMATION The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to legal restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Biovica in any jurisdiction, neither from Biovica nor from someone else. This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. No prospectus will be prepared in connection with the Rights Issue. The Company will prepare and publish a disclosure document in the form prescribed by Regulation (EU) 2024/2809 ("Listing Act") Annex IX. This press release does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the Company. The information contained in this announcement relating to the Rights Issue is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this press release or its accuracy or completeness. Zonda Partners AB are acting for Biovica in connection with the Rights Issue and no one else and will not be responsible to anyone other than Biovica for providing the protections afforded to its clients nor for giving advice in relation to the Rights Issue or any other matter referred to herein. Zonda Partners AB are not liable to anyone else for providing the protection provided to their customers or for providing advice in connection with the Rights Issue or anything else mentioned herein. This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public Rights Issue of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the USA, Australia, Belarus, Canada, Hong Kong, Japan, New Zeeland, Russia, Singapore, South Africa, South Korea, Switzerland or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations. In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it. Please note that an investment in the Company is subject to regulation under the Foreign Direct Investment Act (2023:560), which requires investors, under certain conditions, to notify and obtain approval from the Swedish Inspectorate for Strategic Products. Investors should make their own assessment of whether a notification obligation exists before making any investment decision regarding the Rights Issue. Forward-looking statementsThis press release contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's and the group's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company and the group operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release. Information to distributorsSolely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the offered shares have been subject to a product approval process, which has determined that such shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "Target Market Assessment"). Notwithstanding the Target Market Assessment, distributors should note that: the price of the shares in the Company may decline and investors could lose all or part of their investment; the shares in the Company offer no guaranteed income and no capital protection; and an investment in the shares in the Company is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Rights Issue. For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the shares in the distributor is responsible for undertaking its own target market assessment in respect of the shares in the Company and determining appropriate distribution channels. Contact Anders Rylander, CEOPhone: +46 76 666 16 47E-mail: Anders Morén, CFOPhone: +46 73 125 92 46E-mail: Biovica - Treatment decisions with greater confidence Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: This information is information that Biovica International is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-06-11 08:00 CEST. Attachments Biovica resolves on a fully guaranteed rights issue of approximately SEK 80 million at SEK 0.63 per share SOURCE: Biovica International View the original press release on ACCESS Newswire
Yahoo
4 hours ago
- Yahoo
High Growth Tech Stocks To Watch In Global Markets
Global markets have experienced a positive momentum recently, with U.S. stock indexes climbing for the second consecutive week, led by small-cap stocks and a strong performance in the information technology sector driven by optimism around AI-related advancements. In this context, investors often look for high growth tech stocks that demonstrate resilience and innovation, particularly those that can capitalize on emerging trends like artificial intelligence to potentially drive future growth amidst evolving market conditions. Name Revenue Growth Earnings Growth Growth Rating Shengyi Electronics 22.99% 35.16% ★★★★★★ Shanghai Huace Navigation Technology 24.44% 23.48% ★★★★★★ Intellego Technologies 30.80% 45.66% ★★★★★★ KebNi 21.51% 66.96% ★★★★★★ Pharma Mar 29.61% 44.92% ★★★★★★ eWeLLLtd 24.95% 24.40% ★★★★★★ Global Security Experts 20.56% 28.04% ★★★★★★ Rakovina Therapeutics 40.75% 16.49% ★★★★★★ Elliptic Laboratories 36.33% 78.99% ★★★★★★ JNTC 54.24% 87.93% ★★★★★★ Click here to see the full list of 746 stocks from our Global High Growth Tech and AI Stocks screener. Underneath we present a selection of stocks filtered out by our screen. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Sectra AB (publ) is a company that offers solutions in the medical IT and cybersecurity sectors across Sweden, the United Kingdom, the Netherlands, and other parts of Europe, with a market capitalization of approximately SEK67.82 billion. Operations: Revenue for Sectra primarily comes from its Imaging IT Solutions and Secure Communications segments, contributing SEK2.80 billion and SEK407 million respectively. The company's focus on medical IT and cybersecurity solutions positions it within key European markets including Sweden, the UK, and the Netherlands. Sectra, a leader in cybersecurity and medical imaging IT, is demonstrating robust financial and strategic growth. In the fiscal year ending April 2025, the company reported a significant revenue increase to SEK 3.54 billion from SEK 3.04 billion the previous year, with net income rising to SEK 563.37 million from SEK 428.39 million. This performance is underpinned by a strong R&D focus, as evidenced by their latest innovations in enterprise imaging solutions provided as cloud services—Sectra One Cloud and Sectra Amplifier Service—which enhance scalability and integrate AI seamlessly into clinical workflows. These advancements not only solidify Sectra's market position but also cater to evolving customer needs in healthcare technology, ensuring continued growth in a competitive landscape. Navigate through the intricacies of Sectra with our comprehensive health report here. Explore historical data to track Sectra's performance over time in our Past section. Simply Wall St Growth Rating: ★★★★★☆ Overview: Wuxi Taclink Optoelectronics Technology Co., Ltd. specializes in the development and production of optoelectronic devices, with a market capitalization of approximately CN¥9.67 billion. Operations: The company focuses on producing optoelectronic devices, contributing significantly to its revenue. Its cost structure and financial performance are primarily driven by this core business area. The company's gross profit margin exhibits notable trends, reflecting its operational efficiency in the market. Wuxi Taclink Optoelectronics Technology is distinguishing itself in the optoelectronics sector with a promising growth trajectory, evidenced by an anticipated 39.1% annual revenue increase and a forecasted 44.1% rise in earnings per year. This performance is bolstered by strategic R&D investments, crucial for sustaining innovation and competitiveness within this high-tech industry. Recent corporate activities, including a significant stock split announced for May 2025, reflect the company's proactive approach to enhancing shareholder value and market presence. These developments underscore Wuxi Taclink's potential to capitalize on expanding market demands while continuously evolving its technological capabilities. Dive into the specifics of Wuxi Taclink Optoelectronics Technology here with our thorough health report. Learn about Wuxi Taclink Optoelectronics Technology's historical performance. Simply Wall St Growth Rating: ★★★★★★ Overview: Fositek Corp. specializes in the manufacture and wholesale of electronic materials and components, with a market capitalization of approximately NT$45.18 billion. Operations: The company generates revenue primarily from electronic components and parts, totaling NT$8.73 billion. Fositek's recent performance and strategic decisions underscore its potential within the high-tech sector. With a 75.3% surge in earnings over the past year, outpacing the industry's 14.2%, and an expected annual revenue growth of 26.7%, Fositek is advancing rapidly. The company has also demonstrated a strong commitment to innovation, as evidenced by its R&D investments which are crucial for maintaining competitiveness in technology-driven markets. Moreover, significant corporate actions like amendments to the Articles of Incorporation reflect a proactive stance in governance that could further bolster investor confidence and business resilience. Click here to discover the nuances of Fositek with our detailed analytical health report. Review our historical performance report to gain insights into Fositek's's past performance. Take a closer look at our Global High Growth Tech and AI Stocks list of 746 companies by clicking here. Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes. Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include OM:SECT B SHSE:688205 and TWSE:6805. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
4 hours ago
- Yahoo
InPost And 2 Additional European Value Stocks Trading Below Estimated Worth
As the European markets experience a positive shift with the pan-European STOXX Europe 600 Index rising by 0.90% amid slowing inflation and easing monetary policy from the European Central Bank, investors are increasingly focused on identifying stocks that may be trading below their intrinsic value. In such an environment, a good stock is often characterized by strong fundamentals and resilience to economic fluctuations, making it potentially undervalued despite broader market gains. Name Current Price Fair Value (Est) Discount (Est) Trøndelag Sparebank (OB:TRSB) NOK114.00 NOK223.37 49% Sparebank 68° Nord (OB:SB68) NOK179.38 NOK357.46 49.8% Montana Aerospace (SWX:AERO) CHF19.50 CHF38.68 49.6% Exsitec Holding (OM:EXS) SEK128.50 SEK254.56 49.5% doValue (BIT:DOV) €2.258 €4.45 49.3% DigiTouch (BIT:DGT) €1.89 €3.67 48.5% Airbus (ENXTPA:AIR) €163.92 €325.62 49.7% adidas (XTRA:ADS) €212.90 €415.66 48.8% Absolent Air Care Group (OM:ABSO) SEK212.00 SEK416.49 49.1% ABO Energy GmbH KGaA (XTRA:AB9) €36.70 €72.88 49.6% Click here to see the full list of 182 stocks from our Undervalued European Stocks Based On Cash Flows screener. Here's a peek at a few of the choices from the screener. Overview: InPost S.A. operates as an out-of-home e-commerce enablement platform offering parcel locker services across Poland and other European countries, with a market cap of €7.27 billion. Operations: The company generates revenue through its parcel locker services in Poland and other European nations. Estimated Discount To Fair Value: 40.4% InPost is trading at €14.6, significantly below its estimated fair value of €24.48, suggesting undervaluation based on cash flows. Despite a high debt level and recent volatility in share price, the company forecasts significant earnings growth of 23.8% annually over the next three years, surpassing market averages. Recent earnings show sales growth but a decline in net income year-over-year; however, revenue is expected to grow robustly across regions this year. Upon reviewing our latest growth report, InPost's projected financial performance appears quite optimistic. Dive into the specifics of InPost here with our thorough financial health report. Overview: Mips AB (publ) develops, manufactures, and sells helmet-based safety systems across North America, Europe, Sweden, Asia, and Australia with a market cap of SEK12.21 billion. Operations: The company generates revenue from its helmet safety systems primarily through the Sporting Goods segment, which accounts for SEK516 million. Estimated Discount To Fair Value: 26.9% Mips is trading at SEK 460.8, well below its estimated fair value of SEK 630.38, indicating potential undervaluation based on cash flows. The company has demonstrated strong financial performance with Q1 sales increasing to SEK 116 million and net income rising to SEK 19 million year-on-year. Analysts forecast robust revenue growth of 25% annually and significant earnings expansion at a rate surpassing the Swedish market average, highlighting its attractive growth prospects despite current undervaluation. Our expertly prepared growth report on Mips implies its future financial outlook may be stronger than recent results. Click here to discover the nuances of Mips with our detailed financial health report. Overview: Sonova Holding AG is a global provider of hearing care solutions for both children and adults, with operations spanning Switzerland, the United States, the rest of the Americas, Europe, the Middle East, Africa, and the Asia Pacific; it has a market cap of CHF15.43 billion. Operations: Sonova generates revenue from two primary segments: Hearing Instruments, which accounts for CHF3.57 billion, and Cochlear Implants, contributing CHF307.50 million. Estimated Discount To Fair Value: 39.8% Sonova Holding is trading at CHF 258.8, significantly below its estimated fair value of CHF 429.55, highlighting potential undervaluation based on cash flows. The company's earnings are projected to grow faster than the Swiss market at 10.9% annually, although revenue growth is expected to be moderate at 5.5% per year. Recent leadership changes and confirmed sales guidance for a modest increase further underscore the need for careful monitoring of its strategic direction amidst these transitions. Our earnings growth report unveils the potential for significant increases in Sonova Holding's future results. Delve into the full analysis health report here for a deeper understanding of Sonova Holding. Click through to start exploring the rest of the 179 Undervalued European Stocks Based On Cash Flows now. Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes. Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTAM:INPST OM:MIPS and SWX:SOON. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
